BUSINESS SUMMARY BioMarin Pharmaceutical, Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company�s product portfolio comprises approved products and multiple investigational product candidates. Its approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of genetic disease called mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used for the treatment of mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase. The company also develops various product candidates for the treatment of genetic diseases, which include PEG-PAL, a preclinical enzyme substitution therapy for the treatment of severe PKU; PEG-PAL for phenylketonurics, which are not BH4-responsive; and BH4 for the treatment of various other indications, including cardiovascular indications. In addition, it conducts preclinical development of various other enzyme product candidates for genetic and other diseases, as well as an immune tolerance platform technology to overcome limitations associated with the delivery of protein-based pharmaceuticals. Further, the company holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. BioMarin Pharmaceutical sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Canada, Japan, and the European Union. It has a strategic alliance with Merck Serono S.A.; collaboration with IGAN Biosciences; and joint venture with Genzyme Corporation. The company was founded in 1996 and is headquartered in Novato, California.
$18.06 (10/29/08)
